BRAF and melanoma: Data have recently been published from the TRICOTEL clinical trial, a phase II study with 2 cohorts patients diagnosed with melanoma and BM: one cohort without BRAF V600 mutated tumors, and another one with BRAF V600 mutated ones (73).